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Introduction
Hepatic insulin resistance triggers an atherogenic dyslipidaemia, characterised by high levels of triglyceride-rich very low density lipoproteins (VLDL) and their cholesteryl ester-rich remnant particles, low levels of high density lipoprotein (HDL), and small dense low density lipoproteins (LDL) [1] [2] [3] [4] . Overproduction of large VLDL 1 is driven by increased flux of nonesterified fatty acids from adipose tissue, upregulation of sterol regulatory element binding protein-1c (SREBP-1c), chronic stimulation of de novo lipogenesis, and reduced fatty acid oxidation in the liver [1] [2] [3] [4] . Circulating HDL levels are maintained by hepatic ABCA1 [5] , insulin resistance causes loss of hepatic ABCA1 protein expression [5] [6] [7] [8] [9] and a strong reciprocal relationship exists between ABCA1 expression and hepatic VLDL output [10] [11] [12] [13] ,
integrating triglyceride and cholesterol lipoprotein metabolism. Dysregulated hepatic lipid metabolism also contributes to non-alcoholic fatty liver disease (NAFLD), present in 70-80% of diabetic and obese patients [14] , and a condition which ranges from simple steatosis (SS)
to steatosis combined with necrosis and inflammation (non-alcoholic steatohepatitis; NASH)
which can progress to hepatic fibrosis and cirrhosis [14] [15] [16] [17] [18] . Crucially, hepatic accumulation of free cholesterol exacerbates development of NASH and fibrosis, while correction of cholesterol overload reduces the severity of liver disease [16] [17] [18] . Since NASH confers a 1.8-fold higher mortality, and itself increases risk of type 2 diabetes and cardiovascular disease [14, 15] , it is clear that effective treatments for diabetic dyslipidaemia and NAFLD are urgently needed.
One approach could be to sustain, or improve, the efficiency of intracellular cholesterol transport within the liver, particularly when challenged by exposure to elevated levels of glucose, fatty acids and atherogenic lipoprotein remnants. Non-vesicular trafficking of lipids is mediated, in part, by the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain family. The START domain is a ~210 amino acid helix-grip fold, found in 15 distinct mammalian proteins (STARD1-D15), providing an adaptable hydrophobic lipid binding or sensing site for sterols, bile acids, phospholipids, ceramides and small drug molecules [19] [20] [21] . The prototypic member of this family, steroidogenic acute regulatory protein (StAR; StarD1) is a mitochondrial cholesterol trafficking protein primarily involved in steroidogenesis [19] [20] [21] . In the liver, StAR supplies cholesterol to the cytochrome P450 enzyme, CYP27A1, located on the inner mitochondrial membrane, facilitating metabolism of this sterol via the alternative bile acid pathway [22] [23] [24] [25] . The other member of the StarD1 subfamily, StarD3 (Metastatic Lymph Node 64), is a 54 kDa endosomal cholesterol trafficking protein, variously reported to facilitate trafficking of cholesterol to the endoplasmic reticulum, mitochondria and the plasma membrane [26] [27] [28] [29] . Certainly, overexpression of either StarD1 or StarD3 enhances bile acid synthesis via CYP27A1 in primary rat hepatocytes [23] .
Importantly, our previous work demonstrated that expression of both StarD1 and StarD3 are regulated by lipid-responsive transcription factors [30] , and that overexpression of StarD1, or StarD3, in macrophages enhances expression of ABCA1, and cholesterol efflux to acceptor (apo)lipoproteins [31, 32] . This led to dual hypotheses: that loss of these proteins may be implicated in diabetic dyslipidaemia or steatosis, and that targeting these proteins may help to resolve the problems of low HDL and/or overproduction of VLDL by diabetic liver. Thus, we examined expression of StarD1 and StarD3, members of the StarD1 subfamily of lipid trafficking proteins, and their relationship with dyslipidaemia and hepatic steatosis, in the Zucker (fa/fa) rodent model of genetic obesity [33] , and explored their functional role in lipid synthesis and secretion by genetically manipulating expression of these proteins in rat
McArdle RH7777 hepatoma cells.
Methods
Materials
Apolipoprotein A-I was purchased from Athens Research and Technology (Georgia, USA).
All other materials were from UK companies, or UK suppliers for the companies indicated. [50] . Successful transfection studies, manipulating DGAT-1 and ACAT-1/2 activity, have been performed in this cell line, resulting in altered secretion of apoB lipoproteins [51] .
However, it should be noted that McArdle hepatoma cells differ somewhat in their nutrient partitioning, compared with primary rat hepatocytes [52] . Hansson et al (2004) demonstrated that hepatoma cells had a higher rate of fatty acid uptake (2-fold), and a lower rate of fatty acid oxidation (2-fold), compared with primary hepatocytes. Further, McA-RH7777 cells metabolised glucose to lipids or into oxidation, rather than synthesizing glycogen, unlike primary hepatocytes [52] . It has also been demonstrated that McA-RH777 cells exhibit impaired utilisation of triglycerides derived from recycling of phospholipids, resulting in VLDL particles with a slightly different triglyceride composition than those produced by primary hepatocytes [53] . 
Lipid Analyses
Samples of media were extracted according to Bligh and Dyer (1959) , and cellular lipids using hexane:isopropanol (3:2, v/v), as detailed [30] [31] [32] , and extracts dried under N 2 before resuspension in isopropanol containing rat liver lipids, and separation by t.l.c. using petroleum ether: diethyl ether: glacial acetic acid (90:30:1 by vol.) as the mobile phase. Lipids were identified by comparison with authentic standards, and dpm determined by scintillation counting (Hidex 300SL).
Gene and protein analyses Levels of mRNA encoding StarD1 and StarD3 were measured relative to Gapdh, as described [29] [30] [31] ; specific sequences for primers and fluorescent
Gene expression of Dgat1, Dgat2 and Nrih3, relative to Gapdh, were measured using Results are expressed as ratio to Gapdh, using the 2 -Ct comparison method (Applied Biosystems in obese male and female rats compared to lean rats of the same gender (Fig 1a) . Obese male Zucker rats accumulated greater quantities of hepatic triacylglycerol and phospholipids than obese female rats, while obese female rats were characterized by a more profound hyperlipidaemia (Fig 1a) , providing an interesting model in which to investigate gene expression of cholesterol-binding StarD1 subfamily of lipid trafficking proteins.
Levels of mRNA encoding StarD1 and StarD3, relative to Gapdh, are shown in Figure 1b .
No significant changes in expression of StarD1 were noted in hepatic tissues (n=4) from lean and obese rats, of either gender. By contrast, levels of StarD3 (48%; p<0.01; n=4) mRNA decreased in hepatic tissues from obese, compared to lean male rats; a similar trend, albeit non-significant, was noted in hepatic tissues from obese compared with lean female rats.
While levels of StarD1 protein were low and difficult to detect by Western blotting, as previously noted [25] , expression of StarD3 protein was markedly regulated, and substantively higher (2.27-fold; p<0.001; n=4 and 11.45-fold; p<0.01; n=4) in female lean and obese rats, compared with male lean and obese rats, respectively (Figure 1c) . (Figure 2e) , while knockdown of StarD3 tended to reduce cholesterol efflux slightly (NS) (Figure 2f ). This suggested that increasing hepatic levels of StarD3 could enhance circulating levels of HDL, although this finding requires validation in vivo .
Cholesterol synthesis, esterification and secretion into the medium were also studied in these cell lines, under basal conditions, and following treatment with non-esterified fatty acid to stimulate synthesis and secretion of neutral lipids (Figure 3) . The incorporation (2h) of Figure 4e) . Taken together, these data indicate differential effects of StarD1 and StarD3 overexpression on hepatic triacylglycerol synthesis and/or secretion.
Accordingly, we measured expression of the genes encoding DGAT-1 and DGAT-2 in samples of rodent liver (Figures 5a and 5b) and in StarD1 and StarD3 overexpressing cells, compared with empty vector controls (Figures 5c and 5d ). While no significant differences in hepatic Dgat1 expression were noted in male or female, lean or obese rats, the expression of Dgat2 was significantly higher in obese female rats, when compared with lean female controls (1.86-fold; p<0.01), and with obese male rats (2.3-fold; p<0.01) (Figure 2b ). McA-RH7777 EV controls; a modest repression was seen in StarD1 overexpressing cells (23%), and in StarD3 overexpressing cells (58%). However, we note this latter repression was not seen when this gene was investigated in StarD3 overexpressing cells using commercial Q-PCR arrays (Figure 7b ), suggesting that the level of this transcription factor may fluctuate, or that the low level of expression of this gene may preclude accurate quantitation.
Overexpression of StarD1 in McA-RH7777 cells induced a 2.3-fold change in expression of
The effect of StarD3 knockdown (Figure 2a ) on hepatic lipid synthesis and secretion is shown in Figure 6 . Incorporation of [ 14 C]acetate into cellular cholesterol and cholesteryl ester decreased by 59% (p<0.05) and 81% (p<0.01) (Figure 6a) ; a decrease (71%; p<0.01) in secretion of de novo synthesized cholesteryl ester was also noted (Figure 6b) . 
Discussion
The present study demonstrates hepatic expression of StarD3 protein to be repressed by genetic obesity in both male and female rats. Substantively higher levels of StarD3 protein were also noted in female, compared with male rats, raising the possibility that StarD3 might facilitate lipid export, rather than retention in the liver. Alternatively, it was possible that lack of StarD3 might promote lipid accumulation within the liver and/or impair export in obese male rats. Hepatic levels of StarD1, the other member of this subfamily, were detectable by Q-PCR, but not Western blotting, as previously reported [24] , and also tended to decline somewhat in genetic obesity. Overexpression of rodent StarD1 and StarD3, and knockdown of StarD3, in McArdle hepatoma cells, allowed evaluation of the causal relationship between these proteins, and lipid synthesis and secretion by the liver. In interpreting these data, it is important to recognise that differences exist between McA-RH7777 cells and primary rat hepatocytes: hepatoma cells preferentially utilise fatty acids rather than glucose, which may reflect the demand for lipid substrates to sustain membrane biogenesis in proliferating cells [48] .
Dissection of cholesterol homeostasis in StarD1 overexpressing cells did not yield any significant differences, when compared to the EV; by contrast, overexpression of StarD3 increased the flux of [ 14 C]acetate into the cholesteryl ester pool, and stimulated cholesterol efflux to exogenous apoA-I. The latter finding agrees well with previous studies demonstrating increased expression of ABCA1 and efflux of cholesterol to apoA-I in human macrophages [32] , and with the suggestion that STARD3 can access a pool of cholesterol in 'early' late endosomes, readily amenable to recycling to the plasma membrane [27] .
However, the FFAT motif within an acidic tract in StarD3 interacts with ER-anchored VAP proteins to increase the formation of inter-organelle membrane contact sites between late endosomes and the ER [26] , and StarD3 can also deliver cholesterol to mitochondria [23, 28, 29, 36, 37] . Indeed, enhanced flux of [ 14 C]acetate into the cholesteryl ester pool suggests increased total cholesterol biosynthesis and, therefore, efficient transport of cholesterol away from the ER. Knockdown of StarD3 decreased de novo synthesis of hepatic cholesterol and cholesteryl esters, which implies accumulation of cholesterol at the ER, and may reflect loss of cholesterol delivery from endosomes to the plasma membrane or mitochondria. This conclusion is supported by the modest increases in cholesteryl ester mass noted in mice in which the START domain of StarD3 was deleted [38] .
Analysis of the synthesis of triacylglycerol from differing precursors revealed differential of ABCA1, but also Srebp-1c, triggering lipogenic responses [31] . It is evident that lean female rats express higher hepatic levels of the gene encoding LXR than lean and obese male animals, and that LXR expression also declines with obesity in female rats ( Figure   5e ).
Certainly, StarD3 overexpression induces marked changes in gene expression in McArdle
hepatoma cells, which may variously influence insulin resistance in the liver. For example, induction of PGC1 [40] , insulin receptor substrate 1 [41] and the farnesoid X receptor [42] have been associated with improved mitochondrial function, metabolic responses and/or sensitisation of the liver to insulin. However, increased expression of glucose 6phosphatase, an established target of the transcriptional coactivator function of PGC-1, suggests StarD3 overexpression could exacerbate glycaemia in the fasting state [43] ; moreover, induction of CYP2E1 is thought to enhance oxidative stress, another pathogenic trigger for onset of fatty liver disease [44] . Perhaps most intriguingly, StarD3 overexpression markedly repressed the expression of serpine 1 (plasminogen activator inhibitor 1; PAI1), elevation of which was recently identified as a link between obesity, diabetes and cardiovascular disease [45] .
In summary, the mitochondrial and endosomal cholesterol-trafficking proteins, StarD1 and StarD3, appear to exert differing effects on hepatic lipid metabolism in McArdle hepatoma cells. Mitochondrial StarD1 increases the utilisation of exogenous (preformed) fatty acids for triacylglycerol synthesis and secretion, but impacts minimally on cholesterol homeostasis. By contrast, endosomal cholesterol-trafficking protein, StarD3, appears to impact predominantly on cholesterol efflux to apoA-I, rather than the secretory pathway, and facilitates de novo biosynthesis of neutral lipids. The former suggests one way of improving circulating levels of HDL, while in the latter context, it should be noted that it is not the accumulation of triacylglycerol per se that is damaging to the liver [46] , but rather build-up of biologically active metabolites such as long-chain acyl CoAs, diacylglycerols and ceramides, which can impair insulin signalling and promote inflammatory responses [39] . Indeed, it has been suggested that triacylglycerol accumulation protects against fatty acid-induced lipotoxicity [47] ; no evidence for increased inflammation or apoptosis was noted in StarD3 overexpressing cells. However, the link between StarD3 and DGAT-2 may potentiate the triglyceridaemia associated with Type 2 diabetes. Further, since StarD3 overexpression also induced expression of a number of genes which impact variously on hepatic insulin resistance, further studies on the role of this cholesterol transport protein in diabetic murine models are clearly warranted. Thus, targeting StarD3 may increase circulating levels of HDL and protect the liver against lipotoxicity, while loss of expression of this protein may be part of the pathogenesis associated with hepatic steatosis. 
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